SLE with negative antiphospholipid antibodies (aPL) |
Copper-bearing IUD (A)2929 Sanchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539-49.,3131 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114:341-53. or levonorgestrel-releasing IUD (C)1818 WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. http://www.who.int/reproductivehealth/pu...
,3838 Mc Nicholas C, Peipert JF. Long-acting reversible contraception for adolescents. Curr Opin Obstet Gynecol. 2012;24:293-8.
|
Combined oral contraceptive or progestogen-only pills for stable, mild disease activity (A)2828 Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-8.,2929 Sanchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539-49.,3131 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114:341-53. or DMPA (C)1313 Silva CA, Hilario MO, Febronio MV, Oliveira SK, Almeida RG, Fonseca AR, et al. Pregnancy outcome in juvenile systemic lupus erythematosus: a Brazilian multicenter cohort study. J Rheumatol. 2008;35:1414-8.
|
In “contraceptive accidents” at risk of pregnancy (failure to use) we indicate emergency contraception (NS) |
SLE with positive (or unknown) aPL/antiphospholipid syndrome |
Copper-bearing IUD (NS) or Levonorgestrel-releasing IUD (C)1818 WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. http://www.who.int/reproductivehealth/pu...
|
Progestogen-only pills (B)3131 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114:341-53.,4646 Mantha S, Karp R, Raghavan V, Terrin N, Bauer A, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. or DMPA4848 Yamakami L, Serafini P, de Araujo D, Bonfá E, Leon E, Baracat E, et al. Ovarian reserve in women with primary antiphospholipid syndrome. Lupus. 2014;23:862-7.,4949 Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20:523-6.
|
SLE with severe thrombocytopenia |
Levonorgestrel-releasing IUD (C)1818 WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. http://www.who.int/reproductivehealth/pu...
|
Combined oral contraceptive for stable, mild disease activity (NS) |
Other diseases (juvenile idiopathic arthritis, juvenile dermatomyositis) |
Combined oral contraceptive or other combined hormonal contraceptive (NS) |
Long-acting reversible contraceptive (includes IUD or implant) (NS) |
In “contraceptive accidents” at risk of pregnancy (failure to use) we indicate emergency contraception (NS) |